French life sciences consultancy acquires IntiQuan

Founded in 2015 by Dr. Henning Schmidt, IntiQuan has rapidly emerged as a leader in pharmacometrics and statistical modeling services by offering innovative, tailored solutions that streamline drug development and regulatory processes. IntiQuan excels at transforming complex data into actionable insights across various therapeutic areas, from pre-clinical studies to Phase IV trials. Its team of scientific experts leverages advanced mathematical modeling and simulation techniques to inform clinical study design, as well as analyze and predict trial outcomes. By integrating diverse datasets, IntiQuan informs critical decisions, positioning itself as a key player in advancing precision medicine.

The Basel based company has been acquired by ProductLife Group (PLG), a life sciences Industry reference strategic partner for the development, market introduction and life cycle management of product portfolios, and the related business and digital transformation. Headquartered in Courbevoie, Île-de-France, PLG has a global reach spanning more than 150 countries, with over 1700 experts and 1000+ clients worldwide, including seven of the top ten.

This acquisition allows PLG to add a key set of capabilities focused on significantly reducing development risk, costs and timelines and enhancing patient safety through advanced dose-response analyses and predictive safety profiling. PLG is now in position to offer customers cutting-edge pharmacometrics services that include strategic consulting in pharmacokinetics/pharmacodynamics (PK/PD), population pharmacokinetics (popPK), and biosimulation services. Additionally, this strengthens PLG’s strategy to create a fully integrated global platform, with further expansions planned across the US and European markets, PLG is well on its way to becoming a leading global provider of comprehensive drug development services.

Xavier Duburcq, CEO of PLG, commented: “We are excited to welcome the IntiQuan team to PLG. They are a very strong fit with our expertise-driven organization. Their deep and highly specialized scientific knowledge in pharmacometrics and clinical pharmacology means that we will enhance the support we provide to our clients in their drug development journey.  Pharmacometrics and model-informed drug development offer regulatory grade insights that can impact key decision-making and accelerate clinical development, even eliminating the need for certain trials, in some cases.”

“Joining forces with PLG is a pivotal moment for IntiQuan. Our teams support IntiQuan’s clients by bringing breakthrough medicines to patients and reducing both the time to market and the cost of research and development through our combined solutions. We are excited to contribute our unique capabilities to PLG’s global platform and to play a key role in advancing the future of drug development,” added Henning Schmidt, Founder of IntiQuan.

(Press release/RAN)